CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a section of the National Institutes of Health (NIH), will sponsor preclinical testing of a new oral drug being developed by DiaKine Therapeutics that may prevent or reverse diabetes. In awarding the sponsorship, the NIH reviewers saw “high scientific merit and novelty” in the proposal. The study, part of the type 1 diabetes preclinical testing program (T1D-PTP), is a predecessor to human clinical trials and is necessary to establish “proof of principle” of the new compound.
